Teva's Problems Continue to Mount With No Relief in Sight http://www.zacks.com/stock/news/293077/tevas-problems-continue-to-mount-with-no-relief-in-sight?cid=CS-ZC-FT-293077Feb 21, 2018 - Teva (TEVA) faces significant challenges including rapid erosion in sales of Copaxone and pricing erosion in the U.S. generics business. zc:-78234940463807894410

Neurocrine Biosciences Shows Again That Sometimes The Tortoise Wins https://seekingalpha.com/article/4148380-neurocrine-biosciences-shows-sometimes-tortoise-wins?source=feed_sector_healthcareFeb 20, 2018 - Neurocrine's deliberate approach to pipeline development could lead to four drugs and six indications commercialized over the next four to five years, with multiple $1 billion-plus opportunities. Ingr 0 sa:-1350389348031699700